There is limited real‐world data regarding the efficacy and safety of ivosidenib for patients affected by IDH1 mutant advanced CCA, and it is crucial to bridge this gap mainly for two reasons: (a) the ClarIDHy trial showed a relatively small, albeit statistically significant, absolute gain in terms of PFS compared to placebo; (b) an appropriate comparator was not available when the study was designed [2]. Here, IDH1 is linked to cholangiocarcinoma.